Literature DB >> 17931238

Surgical site infections in cardiac surgery: microbiology.

Bo Söderquist1.   

Abstract

Coagulase-negative staphylococci (CoNS) are the most common bacteria isolated from infections following cardiac surgery. CoNS display various virulence factors, such as toxins, adhesive proteins and biofilm production. The Staphylococcus epidermidis surface (Ses) protein I and the ica operon encoding the polysaccharide intercellular adhesin (PIA) are discussed in more detail. Although several of these virulence factors are prevalent among CoNS isolates causing sternal wound infections, they do not represent a prerequisite for causing an infection and that emphasizes that host factors may be as important.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931238     DOI: 10.1111/j.1600-0463.2007.00833.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  13 in total

1.  Screening cardiac surgery patients for MRSA: an economic computer model.

Authors:  Bruce Y Lee; Ann E Wiringa; Rachel R Bailey; Vishal Goyal; G Jonathan Lewis; Becky Y K Tsui; Kenneth J Smith; Robert R Muder
Journal:  Am J Manag Care       Date:  2010-07-01       Impact factor: 2.229

2.  eComment. A change in the microbial spectrum in deep sternal wound infections.

Authors:  Jan J van Wingerden
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09

3.  Vaccination with SesC decreases Staphylococcus epidermidis biofilm formation.

Authors:  Mohammad Shahrooei; Vishal Hira; Laleh Khodaparast; Ladan Khodaparast; Benoit Stijlemans; Soňa Kucharíková; Peter Burghout; Peter W M Hermans; Johan Van Eldere
Journal:  Infect Immun       Date:  2012-07-16       Impact factor: 3.441

4.  Bacterial growth and wound infection following saphenous vein harvesting in cardiac surgery: a randomized controlled trial of the impact of microbial skin sealant.

Authors:  K Falk-Brynhildsen; B Söderquist; O Friberg; U Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-08       Impact factor: 3.267

5.  Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.

Authors:  S Albac; D Labrousse; D Hayez; N Anzala; D Bonnot; P Chavanet; E Aslangul; D Croisier
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

6.  Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.

Authors:  Saeed A Alqahtani; Abdullah S Alsultan; Hussain M Alqattan; Ahmed Eldemerdash; Turki B Albacker
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 7.  Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus.

Authors:  M Widerström; J Wiström; A Sjöstedt; T Monsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

8.  Wound complications after median sternotomy: a single-centre study.

Authors:  Claudia Heilmann; Rahel Stahl; Christian Schneider; Tetyana Sukhodolya; Matthias Siepe; Manfred Olschewski; Friedhelm Beyersdorf
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-25

9.  Microbe repelling coated stainless steel analysed by field emission scanning electron microscopy and physicochemical methods.

Authors:  Mari Raulio; Mikael Järn; Juhana Ahola; Jouko Peltonen; Jarl B Rosenholm; Sanna Tervakangas; Jukka Kolehmainen; Timo Ruokolainen; Pekka Narko; Mirja Salkinoja-Salonen
Journal:  J Ind Microbiol Biotechnol       Date:  2008-04-01       Impact factor: 3.346

10.  Inhibition of Staphylococcus epidermidis biofilm formation by rabbit polyclonal antibodies against the SesC protein.

Authors:  Mohammad Shahrooei; Vishal Hira; Benoit Stijlemans; Rita Merckx; Peter W M Hermans; Johan Van Eldere
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.